Abstract. Targeted molecular therapies against the epidermal growth factor receptor (EGFR) are novel, promising and potentially radiosensitising therapeutic approaches in the treatment of glioblastoma, a highly malignant and treatmentrefractory brain tumour. Despite a solid rational basis, specific EGFR inhibition has rendered only disappointing clinical results to date. We therefore evaluated the efficacy of additional inhibition of human epidermal growth factor receptor 2 (HER2), the 'non-autonomous amplifier' of EGFR signalling. Glioblastoma cells (LN-18, LN-229) with different co-expression levels of EGFR and HER2 were treated with specific EGFR and bispecific EGFR/HER2 tyrosine kinase inhibitors (TKIs) (AG1478, AEE788) and experimental radiotherapy, followed by assessment of growth inhibition. Activity of the major downstream signalling pathways Akt and MAPK was determined by immunoblotting. EGFR-overexpressing LN-18 cells (EGFR ++++ /HER2 + ) showed resistance and HER2-overexpressing LN-229 cells (EGFR + /HER2 ++ ) showed sensitivity to EGFR-specific inhibition. Interestingly, resistance of LN-18 to EGFR inhibition was overcome by AEE788 treatment, supposedly due to its additional HER2 inhibition. Application of AEE788 resulted in blockage of EGF-dependent EGFR/HER2-heterodimer activation in LN-18 cells, disclosing a possible mediating mechanism for overcoming EGFR-resistance. TKI treatment resulted in significant blockage of both Akt and MAPK signalling pathways, but an incomplete inhibition of PI3K/Akt paralleled the resistance of cells to TKI-induced growth inhibition. Furthermore, the bispecific EGFR/HER2 inhibitor AEE788 showed a radiosensitising effect in EGFR-overexpressing cells. Taken together, we conclude that inhibition of HER2 in EGFRoverexpressing tumours may harbour the potential to overcome resistance to EGFR-targeted therapy and exert radiosensitising properties. We suggest that responsiveness to EGFR targeted therapy is mediated through impairment of EGFR/ HER2 heterodimer signalling, and thus depends on the ratio of EGFR to HER2 rather than on the amount of individual receptors.
Introduction
Glioblastoma (GBM) is the most frequent brain tumour and among the most malignant of all human neoplasms, with dismal patient outcome. In retrospective population-based studies from Switzerland and Canada, the median survival time for all patients is 4.9 months; <20% of patients survived >1 year, and <3% survived >3 years (1, 2) . It is one of the most treatment-refractory tumours and is highly resistant to current standard therapies (i.e., surgery, radiotherapy and chemotherapy). If feasible, maximal surgical resection improves survival, but complete resection is virtually impossible due to the highly infiltrating nature of the neoplasm. Despite all efforts to improve radiation and chemotherapy protocols, the prognosis of patients has changed very little to date (3) . Therefore novel therapeutic agents and approaches are exceptionally desirable.
Novel and highly promising oncological therapies currently under development target and inhibit the activities of specific molecules that contribute to the malignancy and radioresistance of malignant neoplasms. This approach has already resulted in valuable clinically approved pharmacological agents. Perhaps the first success story is a selective inhibitor of the ABL tyrosine kinase (Imatinib mesylate/ Glivec ® ), which proved effective in putting nearly all patients with BCR-ABL-driven chronic-phase CML into complete remission (4) . This proof of concept edified the image of 'oncogenic addiction', the dependence of tumour cells on specific molecular events (5-7).
The rationale for targeting the ErbB or epidermal growth factor receptor (EGFR) family of protein tyrosine kinases in GBM is compelling, as they are known to contribute to malignant processes (8) , and overexpression of EGFR presents a key signalling pathway in de novo GBM (9) . ErbB receptor signalling is induced by ligand dependent homo-or heterodimerisation of individual receptor monomers [EGFR (ErbB1), HER2 human epidermal growth factor receptor 2 (HER2, ErbB2), HER3 (ErbB3) and HER4 (ErbB4)], which triggers signal transduction mainly through the PI3K/Akt-and MAPKpathways (8) . HER2 does not interact with extracellular ligands, but forms a basal level of homodimers due to the constitutive extension of its dimerisation loop. Most notably, however, HER2 acts as a 'non-autonomous amplifier' (10) , it serves as the preferred dimerisation partner for the other ErbB receptors, with signalling potency of HER2-heterodimers markedly exceeding those of receptor-homodimers (8, 10) . Interestingly, in a recent study, co-expression of HER2 was observed in the majority of GBM specimens (>80%), with high expression patterns detectable in de novo GBM (11) . Supposedly due to tumour heterogeneity, other studies rendered lower expression patterns for HER2, but most of them showed co-expression of EGFR and HER2 in the majority of GBM specimens (12) (13) (14) (15) (16) .
One method to inhibit ErbB receptors is the administration of specific small-molecule tyrosine kinase inhibitors (TKIs), cell-permeable agents that compete with ATP at the catalytic domain of the protein tyrosine kinase, thereby inhibiting transphosphorylation of the receptor and downstream signalling. Several EGFRs targeting TKIs proved effective in other solid cancers (17) , but showed only very disappointing effects in GBM (18, 19) . In a recent study, the addition of Erlotinib, a selective EGFR inhibitor, to current standard glioblastoma therapy with Temozolomide and radiation did not show any improvement in overall survival, nor did analyses for EGFR, the truncated EGFR EGFRvIII, p53, phosphatase and tensin homolog (PTEN), combination EGFR and PTEN, and EGFR amplification status predict sensitivity to EGFR inhibition (19) . The failure to predict sensitivity to EGFR-inhibitors from EGFR protein expression may be due to several reasons. Keeping in mind the extensive cross-talk between the ErbB receptor family members, presumably the most important cause is additional tumour dependence on other receptor protein kinases, providing a rationale for concomitant multi-receptor inhibition.
In the present study, we aimed to elucidate the additional receptor dependence of EGFR-TKIs in a preclinical experimental setting. Targeting cell lines expressing an approximately inverse ratio of EGFR and HER2 (LN-18 and LN-229) with specific EGFR-and bispecific EGFR/HER2-inhibiting TKIs (AG1478 and AEE788), we explored the importance of HER2-signalling in GBM and evaluated the major downstream signalling pathways. As ErbB receptors are known to mediate radioprotective cellular effects through Akt and MAPK-signalling (20) and account for at least part of 'accelerated repopulation' (i.e., enhanced cellular proliferation after exposure to ionizing radiation) (21), we finally evaluated the radiosensitising property of TKIs.
Materials and methods
Cell cultivation. Cell lines LN-18 and LN-229 derived from human de novo GBM (22, 23) were maintained as monolayers in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% foetal bovine serum (FBS), 1% L-glutamate, 100 U/ml penicillin and 100 μg/ml streptomycin (Gibco-BRL, Karlsruhe, Germany) in a humidified atmosphere at 37˚C and 5% CO 2 .
Inhibitors. Tyrphostin AG1478 (Sigma-Aldrich, Irvine, UK) is known to be a highly specific EGFR TKI [IC 50 (EGFR) = 0.003 μM; IC 50 (HER2) > 100 μM] (24). The pyrrolopyrimidine AEE788 (kindly provided by Novartis Pharma AG, Basel, Switzerland) represents a bispecific EGFR-/HER2-TKI [IC 50 (EGFR) = 0.002 μM, IC 50 (HER2) = 0.006 μM), with additional potency to inhibit VEGFR2 ( KDR/Flk-1; IC 50 = 0.077 μM) (25) . Specific inhibition of the two major downstream signalling pathways was achieved using the specific PI3-kinase inhibitor LY294002 (Calbiochem-Novabiochem, Schwalbach, Germany) [IC 50 (PI3K) = 1.4 μM; IC 50 (27, 28) . The selectivity of all inhibitors was confirmed in cell-based assays (24) (25) (26) 28) . Inhibitors were dissolved and used according to the manufacturer's specifications.
Western blot analysis. Protein extraction from cultured cells was accomplished using lysis buffer containing 20 mM TrisHCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 1 mM ß-glycerolphosphate, 1 μg/ml leupeptin and 1 mM PMSF.
If cells were treated before lysis, they were serum starved for 12 h, followed by incubation with inhibitors in the concentrations indicated for 1 h and addition of 10 ng/ml EGF (Upstate Biotechnology, NY, USA) for 5 min.
Lysates were clarified by centrifugation and their protein concentrations were determined using the Bradford reagents according to the manufacturer's specifications (Bio-Rad Laboratories Inc., Munich, Germany).
Equal amounts of protein were resolved on sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to polyvinylidene difluoride (PVDF) membranes (Immobilion Millipore Corporation, Bedford, USA) and incubated with the specific primary antibodies, rabbit polyclonal anti-EGFR (1:1,000; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), rabbit polyclonal anti-HER2 (1:500; DakoCytomation, Glostrup, Denmark), rabbit polyclonal antiAkt (1:1,000), rabbit polyclonal anti-pAkt (Ser473; 1:1,000), rabbit polyclonal anti-p42/44 MAPK (1:1,000), rabbit polyclonal anti-pp42/44 MAPK (Thr202/Thr204; 1:1,000) and the respective goat polyclonal anti-rabbit and sheep polyclonal antimouse horseradish peroxidase (HRP)-conjugated secondary antibody (1:2,000; unless otherwise indicated, all antibodies were from Cell Signaling Technology Inc., Beverly, MA, USA). Where necessary, the mouse monoclonal anti-·-tubulin antibody (Sigma-Aldrich) was applied to stain ·-tubulin as a loading control.
Blots were developed using SuperSignal chemiluminescent substrates from Pierce (Perbio Science, Bonn, Germany). Densitometric band analysis was performed using ImageJ Software 1.37v (developed at the US National Institutes of Health and available on the Internet at http://rsb.info.nih. gov/ij/).
Immunoprecipitation. Following a 24-h deprivation from FBS, cells were treated in duplicate with 1 and 10 μM AEE788 for 30 min before addition of 10 ng/ml EGF. Protein extraction was performed using lysis buffer containing 10 mM Tris-HCl (pH 7.4), 130 mM NaCl, 5 mM EDTA, 1% Triton X-100, 20 mM sodium phosphate (pH 7.5), 10 mM sodium pyrophosphate (pH 7.0), 50 mM NaF, 1 mM sodium orthovanadate, 1 mM ß-glycerolphosphate and protease inhibitors (Roche Diagnostics, Mannheim, Germany).
After clarification by centrifugation and preclearing with protein A-Sepharose (Amersham/Pharmacia Biotech, Freiburg, Germany), 5 μM anti-EGFR antibody was added to the supernatant. The addition of an anti-mouse antibody (Jackson ImmunoResearch, Baltimore) to one probe served as a negative control for unspecific binding. Antibody-protein complexes were precipitated with protein A-Sepharose. For immunoblotting control, whole cell lysates and bound fractions, respectively, were subjected to SDS-PAGE and blotted on PVDF membranes. Detection of phosphotyrosine was performed using a mixture of the antiphosphotyrosine monoclonal mouse antibodies 4G10 (1:2,000; Upstate Biotechnology) and pY20 (1:2,000; PharMingen, Heidelberg, Germany). After incubating blots with HRP-conjugated secondary antibody (1:10,000; polyclonal sheep anti-mouse and donkey anti-rabbit, respectively, Amersham/Pharmacia Biotech) they were developed using SuperSignal chemoluminescent substrates from Pierce (Perbio Science). Subsequently, the antibodies were stripped and the membranes reprobed with anti-EGFR or anti-HER2 antibodies. For evaluation of cytotoxicity, either the absorbance measurement values were plotted directly as arbitrary units or cell growth in each well was calculated as the percentage of the average absorbance of the untreated control.
Colony formation assay. The effects of bimodal treatment (TKI/irradiation) were measured by assessing the colony formation ability of cells, a method representing the radiobiologic gold standard (29) .
Cells were plated into 24-well dishes at 2x10 4 cells/well and treated with a single administration of 5 μM AG1478 or AEE788. After 12 h, cells were Á-irradiated with single doses of 0-10 Gy using a cobalt 60 Co source (6 MeV) at a dose rate of 6 Gy/min. Cells were harvested 48 h after inhibitor-treatment. They were then diluted (1:200) and plated into 6-well dishes. After a 10-day incubation, cells were fixed and stained using DiffQuik reagents (Medion Diagnostics AG, Düdingen, Switzerland). A flat bed scanner was used to acquire RGB colour images of the culture dishes at a resolution of 300 pixels per inch (ppi), which were converted to grey-scale images, followed by automated counting of colonies by image analysis (30) . Colonies consisting of >50 cells were counted. The surviving fraction was calculated as the percentage of colonies relative to controls.
Surviving fractions determined with the colony formation assay were fitted into the classical linear-quadratic equation, S = exp(-·D -ßD 2 ), where S is the surviving fraction, D the radiation dose and · and ß adjustable parameters (29) . The 95% confidence band was plotted for each survival curve. Calculations were made through nonlinear least-squares regression using GraphPad Prism software, version 5 (GraphPad Software Inc, La Jolla, CA, USA). (Fig. 1) . In both cell lines the difference between EGFR and HER2 expression was highly significant (p<0.001) (Fig. 1A) .
Effect of the bispecific EGFR/HER2 tyrosine kinase inhibitor AEE788 on EGFR/HER2 heterodimer signalling in glioma cell lines.
As shown in earlier studies, AEE788 acts as a bispecific inhibitor of EGFR and HER2 (25) . To elucidate its biological effect on glioma cells, we first verified its impact on EGFR and HER2 signalling. Representative serum-starved LN-18 cells were treated with increasing concentrations of AEE788 and EGF, followed by immunoprecipitation of EGFR. Receptor-activation (i.e., phosphorylation) was then visualised by strong phosphotyrosine immunoreactivity and was found to be EGF-dependent (Fig. 2, upper panel) . The absence of phosphotyrosine immunoreactivity represented the potency of AEE788 to block receptor activation (Fig. 2,  upper panel) . Of interest, HER2 detection in the immunoprecipitated lysate (Fig. 2, lower panel) suggested pronounced EGFR/HER2-heterodimer formation, consistent with HER2 being the preferred dimerisation partner for all ErbB receptors (8) . Stimulation with EGF produced marked receptor phosphorylation and downregulation of total EGFR and HER2 (Fig. 2, second row) , a phenomenon known to take place following receptor activation (8) .
Taken together, we have shown that 1 μM AEE788 (32) causes complete inhibition of EGF-induced EGFR and EGFR/HER2 activation in LN-18 cells and furthermore impairs receptor downregulation, as indicated by strong protein bands of total EGFR and HER2. EGF-dependent EGFR/HER2 heterodimer formation was found to remain unchanged following AEE788 treatment (Fig. 2, middle and lower panel) ; however, the activation (phosphorylation) of EGFR/HER2 heterodimers was clearly inhibited (Fig. 2, upper panel) . Similar results were found for LN-229 cells by Failly et al (32) .
Growth-inhibiting effects of AEE788 in LN-18 and LN-229 glioma cell lines.
Kinetic experiments with increasing concentrations of AEE788 (0.1-25 μM) were conducted in both cell lines, evaluating its growth inhibiting effect at up to 48 h following single dose treatment (Fig. 3) .
In LN-18 cells, a minor, though significant growthinhibition induced by 1 μM AEE788 was assessed at 48 h treatment only (p<0.001; as compared to the untreated control), whereas 5 μM AEE788 exerted a marked growth-inhibiting effect (p<0.05 at 12 h, p<0.001 at 18-48 h) (Fig. 3A, upper   panel) . In LN-229 cells, all applied dosages starting at 0.1 μM AEE788 resulted in marked growth inhibition (p<0.001 at 12, 18, 24, 36 and 48 h; as compared to the untreated control), and there was no significant difference between 1 versus 5 μM AEE788 (Fig. 3A, lower panel) . In both cell lines, 10 and 25 μM AEE788 were shown to act in an excessively cytotoxic manner, possibly due to a loss of specificity for EGFR and HER2 inhibition.
Different reaction of LN-229 and LN-18 cells to EGFRspecific (AG1478) versus bispecific EGFR/HER2 inhibition (AEE788).
In the kinetic experiments stated above, 5 μM AEE788 exerted marked, yet not overshooting growthinhibiting effects in both cell lines compared to untreated controls. To elucidate whether these effects were mediated through specific EGFR inhibition, cells were exposed to equimolar doses of AG1478 and AEE788, and the assay was terminated 48 h later by staining with crystal violet. The results disclosed a different behaviour of LN-18 and LN-229 cells exposed to AG1478 or AEE788. LN-229 cells (EGFR + /HER2 ++ ) reacted equally well to both compounds, showing a uniform decrease of the surviving fraction by ~50% (Fig. 3B) . Conversely, LN-18 cells (EGFR ++++ /HER2 + ) responded in a clearly different fashion to treatment with AG1478 versus AEE788 (p<0.001). Sole EGFR inhibition with 5 μM AG1478 had no significant effect compared to control (p>0.05), whereas 5 μM AEE788 resulted in significant growth-inhibition (p<0.001), most likely due to additional HER2 inhibition (Fig. 3B) .
In conclusion, we have shown the HER2-overexpressing cell line LN-229 to be relatively sensitive to sole EGFR inhibition. Most interestingly, however, the EGFR-overexpressing cell line LN-18 showed a relative resistance to sole EGFR inhibition, which could be overcome by treatment with AEE788, supposedly due to its additional HER2 inhibition.
Inhibition of EGFR and HER2 with TKIs and its effect on the Akt and MAPK signalling pathways in LN-18 versus LN-229 cells. Downstream effects of EGFR and EGFR/HER2
signalling are known to be mediated, in a large measure, by the MAPK and the PI3K/Akt pathways (8) . Thus, it was of interest to investigate the effect of AG1478 and AEE788 on the activation of Akt and MAPK.
Immunoblot analyses revealed a similar TKI-induced reduction of phosphorylated (i.e., activated) MAPK in both cell lines, AEE788 proving more potent than specific EGFR inhibition using AG1478 in both cell lines (Fig. 4A and B) . Thus, MAPK inhibition was found to be an important mediator of TKI treatment, but could not explain the differing behaviour of LN-18 versus LN-229 cells to sole EGFR inhibition.
In LN-229 cells phosphorylation of Akt was equally strongly impeded by both AG1478 and AEE788, even at low inhibitor dosages. Conversely, and most interestingly, Akt phosphorylation in LN-18 cells was blocked more efficiently by AEE788 than by AG1478. In addition, it was clearly dose-dependent (Fig. 4C ). This appears to suggest that relative resistance of LN-18 cells to the effects of AG1478 (specific EGFR inhibition) and its overcoming by AEE788 (additional HER2 inhibition) may, to some extent, be mediated through the Akt signalling pathway.
This finding was further explored by evaluating growthinhibiting effects induced by specific inhibition of the PI3K/ Akt-pathway by LY294002 versus the specific inhibition of the MAPK pathway by PD98059. Both cell lines reacted equally well to PI3K inhibition by LY294002, but LN-18 cells showed a relative resistance for the MEK inhibitor PD98059, paralleling the relative resistance of LN-18 cells to specific EGFR inhibition (AG1478) (data not shown). These results are in favour of the assumption that together with MAPK inhibition, PI3K/Akt-pathway inhibition may be crucial for the growth-inhibiting effect of TKIs.
Radiosensitising property of the bispecific EGFR/HER2 inhibitor AEE788 on LN-18 glioma cells.
To examine whether receptor inhibition was able to alter radiation survival, LN-18 and LN-229 cells were exposed to inhibitors with or without combined Á-irradiation with single doses of 2-10 Gy. The colony-forming potential was evaluated after a 10-day incubation ( Fig. 5A and B) . We chose to apply the inhibitor dosage of 5 μM as it caused marked, yet not overshooting growth inhibition in both cell lines (Fig. 3) . Furthermore, experiments using higher dosages of AEE788 revealed excessive cytotoxicity, leaving no space for evaluation of radiation-induced effects (Fig. 3A) . A detailed analysis of the dose-response was conducted by fitting the survival curves into the linear-quadratic model (29) (Fig. 5C ). Both cell lines showed dose-dependent growth-inhibiting effects induced by irradiation with and without TKIs (Fig. 5) . D 37 , the radiation dose reducing survival to 1/e=0.37 of that in controls, was computed for each survival curve, and the dose enhancement ratio (DER) for each inhibitor was acquired by comparison of D 37 of TKI-treated cells to controls.
In irradiated LN-229 cells (EGFR + /HER2 ++ ) only a trend toward increased growth inhibition after treatment with both EGFR and EGFR/HER2 inhibitors was discernable (DER >1), which did not reach statistical significance (overlapping 95% confidence bands; Fig. 5C ).
Conversely, in LN-18 cells (EGFR ++++ /HER2 + ) treated with 5 μM AEE788, the DER was 1.23 and D 37 differed to TKI-untreated controls on the 5% niveau (non-overlapping 95% confidence bands) starting at a dose of 6 Gy. However, the sole EGFR inhibition failed to significantly reduce the radiation dose needed to reduce cell survival to 37% (Fig. 5C ). (-·D -ßD 2 ), where D is the radiation dose and · and ß adjustable parameters. D 37 is the radiation dose resulting in 37% survival compared to non-irradiated controls. Doseenhancement ratio (DER) was calculated as the quotient of D 37 (radiation alone) and D 37 (radiation plus inhibitor). Points represent the average of three independent experiments and error bars depict the SD. Dotted lines represent the 95% confidence band of DMSO-survival curves and solid grey lines the 95% confidence band of AG1478/AEE788-survival curves. Calculations were made using Graph Pad Prism software, version 5 (GraphPad Software Inc).
In summary, this result indicates a moderate radiosensitising property of the bispecific EGFR/HER2 inhibitor AEE788 in the EGFR-overexpressing glioma cell line LN-18.
Discussion
Due to thus far disappointing results in the EGFR-targeted treatment of glioblastoma (18, 19) , and considering the important ability for cross-talk between the members of the ErbB-receptor family (33), we aimed to evaluate the importance of HER2 signalling and concomitant EGFR/HER2 inhibition in this highly malignant neoplasm.
Using a model of two glioblastoma cell lines with an approximately inverse ratio of EGFR and HER2 together with wild-type PTEN status (22), we demonstrated a relative resistance of presumably EGFR-driven LN-18 cells (EGFR ++++ /HER2 + ) to specific EGFR inhibition with AG1478. Interestingly, HER2-overexpressing LN-229 cells, harbouring only comparably low levels of EGFR (EGFR + /HER2 ++ ), reacted relatively sensitively to specific EGFR inhibition.
Of course, the complex nature of ErbB signalling precludes any rushed conclusion, and further studies are needed to verify the present results. Although our results at least presumably indicate that overexpression of EGFR in tumour cells expressing comparably less HER2 may not only fail to serve as a positive predictive marker for response to EGFR-targeted therapy, but may even render cells resistant to it. It may therefore be possible to explain why EGFR expression in various tumours has not proven to be a useful predictive marker to EGFR-targeted therapies in either preclinical studies, in which EGFR inhibition resulted in growth arrest of tumours expressing a wide range of EGFR levels (34, 35) , or in clinical settings (36, 37) . Conducting cellbased and xenograft experiments using the specific EGFRTKIs AG1478 or gefitinib, it was even suggested that HER2 overexpression indicates responsiveness to EGFR-targeted therapy (38) (39) (40) . Our data are consistent with this observation, though we additionally point out that rather than total receptor amount, it may be the ratio of EGFR to HER2 that determines response to EGFR-targeted therapy. In support, a recently published corresponding observation revealed that the susceptibility of breast cancer cells to anti-HER2 targeting (using Trastuzumab) (to some extent) depends on the degree of EGFR co-expression rather than the individual HER2 amount (41) .
Furthermore we showed some evidence that one mechanism for overcoming resistance to EGFR-targeted therapy might be to additionally target HER2 with bispecific EGFR/HER2 TKIs. EGFR-overexpressing and HER2 coexpressing LN-18 cells (EGFR ++++ /HER2 + ) showed a relative resistance to specific EGFR inhibition using AG1478, which could be overcome by AEE788, supposedly due to its bispecific EGFR and HER2-inhibiting activity.
These results somehow challenge the more orthodox interpretation of 'oncogenic addiction' (5-7), which focuses on one single target molecule. As they suggest, the sole blockade of the prominently overexpressed receptor might not be sufficient for interference with survival pathways. Focus is shifted to associated co-expressed molecules as important concomitant targets.
A conclusive hypothetical explanation for our observation could be the impaired EGFR/HER2 heterodimer activation and thus impaired downstream signalling induced by bispecific EGFR/HER2 inhibition in LN-18 cells and both EGFRspecific and bispecific EGFR/HER2 inhibition in LN-229 cells. Signalling through HER2 heterodimers is widely accepted to be superior in strength and duration over ErbB homodimer signalling (8) , and EGFR/HER2 heterodimers are preferentially formed following EGF stimulation (31) . This enhanced signalling potency and preferred formation have identified EGFR/HER2 heterodimers as one of the main effectors of the oncogenic potential of ErbB receptors, and thus pivotal for the proliferation of ErbB-dependent cancer cells and presumably important for TKI-induced growth inhibition.
Transferring this knowledge into a mechanistic explanation of the present findings, EGFR inhibition in EGFR-overexpressing LN-18 cells (EGFR +++ /HER2 + ) does not interfere with EGFR/HER2 heterodimer signalling, and hence induces no growth inhibiting effect. It is therefore implied that due to EGFR overexpression, the total amount of EGFR is only partially blocked by the specific EGFR TKI AG1478. Concomitant inhibition of the comparably lower amount of HER2, implying a complete receptor blockade due to the low receptor number, impairs heterodimer activation, which induces marked growth inhibition.
In LN-229 cells (EGFR + /HER2 ++ ) harbouring comparably less EGFR while overexpressing HER2, sole EGFR inhibition is sufficient to inhibit activation of EGFR/HER2 heterodimers, a complete blockage of EGFR is implied by both EGFR and EGFR/HER2 TKIs.
In support of this hypothetical model and the importance of heterodimer signalling, recent clinical observations disclosed an adverse prognostic value of HER2 overexpression in breast cancer patients only when HER2 was in the activated (i.e., phosphorylated) state or co-expressed with EGFR (42) . A total of 97% of tumours expressing activated HER2 coexpressed EGFR (42) , highlighting the importance and prognostic value of ligand-dependent, i.e., ErbB dimerisation partner-dependent mechanisms of HER2 activation. In another clinical observation in patients with non-small cell lung cancer, sensitivity of EGFR-positive tumours treated with the specific EGFR-inhibitor gefitinib was associated with increased copy numbers of the HER2 gene (43) .
Our data further indicate that together with MAPK inhibition, particularly inhibition of the PI3K/Akt pathway correlates with the growth suppressing effects of EGFR and EGFR/HER2 inhibition, suggesting that the PI3K/Akt pathway may be important in driving tumour growth in both EGFR and HER2-overexpressing GBM. Consistently, activation of the PI3K/Akt pathway has been found to be associated with reduced survival of glioma patients, and it is significantly more frequent in GBM than in non-GBM astrocytic tumours (44) . We hypothesise that the relative resistance of LN-18 cells to sole EGFR inhibition may be partially caused by an incomplete blockage of Akt signalling, which can be overcome by additional inhibition of HER2. This claim is consistent with a recent clinical study disclosing Akt phosphorylation as the strongest predictor of a lack of response to EGFR-targeted therapy in GBM (45) .
Another propensity of ErbB receptors shows their inhibition to be especially valuable to amend radiotherapy treatment in GBM. It is known that ErbB receptors are activated by ionising radiation to produce radioprotective cellular responses, and thereby account for at least part of the radioresistance of cancer cells (20, 21) . This leads to the assumption that inhibition of ErbB receptors with TKIs may prove to be a valuable approach to radiosensitising. Matching expectations, EGFR inhibitors have to date proven to exert some radiosensitising properties in preclinical and clinical settings in various solid tumours, even though controversial results have also been reported (46) . In GBM cell-based studies, it was even shown that inhibition of the Akt signalling pathways with the PI3K inhibitor LY294002 mediates radiosensitisation (47) . Unfortunately, however, LY294002 is not suitable for clinical use owing to its small therapeutic window (48) , and EGFR-targeted therapy and irradiation in GBM patients to date has shown only disappointing clinical results (19, 49) . This leads to the need to augment preclinical understanding of underlying principles of ErbB inhibitionmediated radiosensitisation.
We therefore aimed to evaluate the benefit of EGFR and HER2 inhibition following radiotherapy of glioma cells. Specific EGFR inhibition had no radiosensitising effect in EGFR-driven LN-18 cells (EGFR ++++ /HER2 + ) or in HER2-overexpressing LN-229 cells (EGFR + /HER2 ++ ). Most interestingly though, the bispecific EGFR/HER2 inhibitor AEE788 showed a moderate propensity to radiosensitise LN-18 glioma cells, which overexpress EGFR and co-express HER2. This data further underline the potential of inhibition of HER2 and the impairment of EGFR/HER2 heterodimers in EGFR-driven tumours, a finding that may be of clinical significance and warrants further investigation. Although the dose enhancement ratio of AEE788 in LN-18 cells was only moderate in vitro (DER = 1.23), it may well translate to substantial synergy in vivo, as reported in similar settings (50) . Considering fractionated administration of radiation, the moderate DER of 1.23 per fraction (reported in this study) for each of, for example, 15 fractions would result in a substantial total enhancement ratio of 22.3 (1.23 15 ). Additionally, effects on in vivo tumour microenvironments, such as angiogenesis, may further promote in vivo efficacy. ErbB tyrosine kinase inhibitors have been described to block the secretion of angiogenic factors, such as vascular endothelial growth factor (VEGF) and interleukin-8 (51), and AEE788 is known to exert direct anti-angiogenic activity through additional vascular endothelial growth factor receptor (VEGFR)-inhibition (25) .
Considering the findings, the limitations of the present study should be kept in mind. Although the cell lines used presented a similar molecular status to some important molecules, e.g., PTEN, this does not exclude other molecular alterations influencing the response to the therapies applied. Despite the very low expression of VEGFR2 found by others and our group in preliminary Western blot analyses in both cell lines (data not shown) (52) , it cannot be ruled out that some of the additional effects observed with AEE788 could be affected by VEGFR2 inhibition. Further studies using additional models, e.g., engineered cell lines, additional TKIs, direct receptor-binding studies and investigation regarding cell cycle, apoptosis and invasion/migration, should follow the present work in order to validate the presented hypothesis.
Especially in the context of the highly complex nature of ErbB receptor signalling, there is no doubt that the conclusion that HER2 expression may represent a mechanism of resistance to EGFR-targeted TKIs in glioblastoma may be a simplified approach. Mechanisms of resistance, and most importantly, mechanisms with the potential to overcome resistance to EGFR-TKI therapy, however, are desperately needed. In the present study, our data reveal the potential of HER2 heterodimer signalling to be a mechanism of resistance to EGFRtargeted TKIs. We believe this idea to be an important finding worth communicating.
It clearly cannot be assumed that results obtained on cell lines in vitro can be translated directly into the clinic. Nonetheless, preclinical studies arise as a sine qua non for successful clinical applications, providing insight into molecular characteristics that render patients susceptive to individualised and targeted therapy. We suggest that although EGFR TKIs are developed as 'targeted therapies' selective for EGFR-overexpressing tumours, there is evidence that their clinical testing should not be confined to patients with EGFRoverexpressing neoplasms.
In conclusion, the results of the present study propose the importance of EGFR/HER2 heterodimer receptor signalling in the EGFR-targeted therapy of glioblastoma. Our data indicate that resistance of EGFR-overexpressing tumours to selective EGFR inhibition (AG1478) may, to some extent, be overcome through AEE788, supposedly due to its concomitant HER2 inhibiting effect. In addition, we postulate that response to EGFR-targeted therapy may rather depend on the cellular ratio of EGFR to HER2 than on the total individual receptor amount. Further studies are needed to validate this hypothesis.
